Michelle R. Lofwall, MD

Medical Director of UK College of Medicine Straus Clinic

Practice areas

Practice areas

Clinical interests

  • Addiction Psychiatry
  • Opioid Use Disorders
  • Research

Michelle R. Lofwall, MD

Medical Director of UK College of Medicine Straus Clinic


Dr. Michelle Lofwall discusses Opioid Research

My name is Michelle Lofwall; I received my medical degree from Chicago Medical School. I then completed a fellowship at Johns Hopkins Hospital, Baltimore. I am board certified by the American Board of Psychiatry and Neurology in Psychiatry.

Faculty rank

Associate Professor of Behavioral Science and Psychiatry
Faculty in UK Center on Drug and Alcohol Research


Chicago Medical School

Johns Hopkins Hospital, Baltimore

Johns Hopkins Hospital, Baltimore

Certifications or Special training
American Board of Psychiatry and Neurology, Psychiatry
Diplomate of American Board of Addiction Medicine


UK HealthCare
Lexington KY 40536-0284

Call 859-257-1000
Call 800-333-8874

Insurance information

Insurance policies can vary widely. Please check with your doctor/clinic for specific insurance information before your visit or procedure to avoid unexpected out-of-pocket costs. See list of insurers »

Referral form for physicians »


Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial. JAMA. 2016 Jul 19;316(3):282-90.

Lofwall MR, Babalonis S, Nuzzo PA, Elayi SC, Walsh SL. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend. 2016 Jul 1;164:143-50.

Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. Neuropsychopharmacology. 2016 Jul;41(8):1974-82.

Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. Drug Alcohol Depend. 2016 May 1;162:190-8.

Babalonis S, Lofwall MR, Nuzzo PA, Walsh SL. Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans. Addict Biol. 2016 Jan;21(1):146-58.